Search details
1.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
Cell
; 175(7): 1731-1743.e13, 2018 12 13.
Article
in English
| MEDLINE | ID: mdl-30503213
2.
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
Eur J Heart Fail
; 22(12): 2272-2289, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33094495
3.
Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.
Clin Breast Cancer
; 15(1): 60-5, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25239224
4.
Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
J Clin Oncol
; 33(31): 3576-82, 2015 Nov 01.
Article
in English
| MEDLINE | ID: mdl-26077241
5.
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
J Clin Oncol
; 31(19): 2485-92, 2013 Jul 01.
Article
in English
| MEDLINE | ID: mdl-23715582
Results
1 -
5
de 5
1
Next >
>>